Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Issue 2 (12th October 2009)

• Record Type: Journal Article
• Authors: Konstas, Anastasios G P; Holló, Gábor; Mikropoulos, Dimitrios; Tsironi, Sevasti; Haidich, Anna-Bettina; Embeslidis, Theodoros; Georgiadou, Irene; Irkec, Murat; Melamed, Shlomo
• Is Part Of: British journal of ophthalmology. Volume 94:Issue 2(2010)
• Page Start: 209
• Page End: 213
• Publication Date: 2009-10-12
• Subjects: Exfoliative glaucoma -- bimatoprost -- bimatoprost/timolol fixed combination -- intraocular pressure -- drugs -- treatment medical -- clinical trial; Ophthalmology -- Periodicals; 617.7
• DOI: 10.1136/bjo.2008.155317
• Languages: English
• ISSNs: 0007-1161

Abstract

Abstract : Aim: To compare 24 h intraocular pressure (IOP) control of morning and evening administered bimatoprost/timolol fixed combination (BTFC) and evening administered bimatoprost in exfoliative glaucoma (XFG). Methods: One eye of 60 XFG patients was included in this prospective, observer-masked, crossover comparison. Following wash-out, all patients received bimatoprost monotherapy for 6 weeks. They were then randomised to morning, or evening, administered BTFC for 3 months and then switched to the opposite therapy. Results: At baseline, mean 24 h pressure was 29.0 mm Hg. Bimatoprost reduced the mean IOP by 8.1 mm Hg (27.8%, p<0.001). The evening administration of BTFC reduced 24 h IOP to a statistically lower level than morning administration (10.2 mm Hg (35.3%) vs 9.8 mm Hg (33.8%); p=0.005). Both dosing regimens reduced IOP significantly more than bimatoprost (p≤0.006, for all time points). A 24 h IOP reduction ≥30% was seen in 43 patients (72%) with evening BTFC compared with 39 patients (65%) with morning BTFC (p=0.344) and only 24 patients (40%) with bimatoprost monotherapy (p<0.001 vs both BTFC regimens). Conclusion: Both BTFC dosing regimens significantly reduce 24 h IOP in XFG compared with bimatoprost monotherapy. The evening dosing gives rise to statistically better 24 h IOP control and could be considered in these patients.